{"commentary":{"count":30,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":27,"podcast":2,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02417662\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SARON","nct_id":"NCT02417662","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=saron-nct02417662. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"SARON","arms":[{"description":"The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.","label":"Systemic Anti-Cancer Therapy (SACT) alone","type":"ACTIVE_COMPARATOR"},{"description":"SACT followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites.\n\nThe choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.","label":"SACT + Radical Radiotherapy (Conventional RT and SABR)","type":"EXPERIMENTAL"}],"collaborators":["Cancer Research UK"],"completion_date":{"date":"2028-08","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":140,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Radical Radiotherapy (Conventional RT and SABR)","type":"RADIATION"},{"name":"Non-investigational SACT","type":"OTHER"}],"last_update":"2026-05-06","lead_sponsor":"University College, London","official_title":"Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. A Randomised Phase II Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2026-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"From date of randomisation to the date of death, up to 36 months"}],"references":[{"citation":"Conibear J, Chia B, Ngai Y, Bates AT, Counsell N, Patel R, Eaton D, Faivre-Finn C, Fenwick J, Forster M, Hanna GG, Harden S, Mayles P, Moinuddin S, Landau D. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open. 2018 Apr 17;8(4):e020690. doi: 10.1136/bmjopen-2017-020690.","pmid":"29666135","type":"DERIVED"}],"start_date":{"date":"2016-08-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT02417662"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/saron-nct02417662"}